ArticleOpen forum infectious diseases2017
Extended Screening Costs Associated With Selecting Donors for Fecal Microbiota Transplantation for Treatment of Metabolic Syndrome-Associated Diseases.
Article in Open forum infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05790356 (Fecal Microbial Transplantation for Rheumatoid Arthritis Trial), which is not on this map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Fecal Microbial Transplantation for Rheumatoid Arthritis Trial
Who cites it
33 citing papers in PubMed, 53 citations in OpenAlex.
- Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial.Nature medicine · 2026Trial
- Transient colonization with Blastocystis spp. after transmission via fecal microbiota transplantation.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Trial
- Multi-omic profiling a defined bacterial consortium for treatment of recurrent Clostridioides difficile infection.Nature medicine · 2025Trial
- Exploring factors influencing university students' participation in fecal microbiota donation: a descriptive qualitative study.Frontiers in public health · 2026Article
- Health economic evaluations of fecal microbiota transplantation for non-clostridioides difficile related diseases: a systematic review.Health economics review · 2025Article
- Article
- Microbiome Therapeutics for Clostridioides difficile Infection.Infectious disease clinics of North America · 2025Review
- The gut microbiome as a target in cancer immunotherapy: opportunities and challenges for drug development.Nature reviews. Drug discovery · 2025Review
- Improved survival in advanced melanoma patients treated with fecal microbiota transplantation using healthy donor stool in combination with anti-PD1: final results of the MIMic phase 1 trial.Journal for immunotherapy of cancer · 2025Article
- Microbes as medicine.Annals of the New York Academy of Sciences · 2024Review
- The Role of Fecal Microbiota Transplantation in IBD.Microorganisms · 2024Review
- Fecal microbiota transplantation: current challenges and future landscapes.Clinical microbiology reviews · 2024Review
- High carriage rate of extended-spectrum β-lactamase Enterobacterales and diarrheagenic Escherichia coli in healthy donor screening for fecal microbiota transplantation.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2023Article
- Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial.Nature medicine · 2023Article
- The Impact of Nutrition, Physical Activity, Beneficial Microbes, and Fecal Microbiota Transplant for Improving Health.Life (Basel, Switzerland) · 2023Review
- Improved MAIT cell functions following fecal microbiota transplantation for metastatic renal cell carcinoma.Cancer immunology, immunotherapy : CII · 2023Article
- Washed preparation of faecal microbiota changes the transplantation related safety, quantitative method and delivery.Microbial biotechnology · 2022Article
- Donor Screening Revisions of Fecal Microbiota Transplantation in Patients with Ulcerative Colitis.Journal of clinical medicine · 2022Article
- Article
- Fixing Functional GI Disorders Using Microbes: Easier Said Than Done.Frontiers in endocrinology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKnowledge of the impact of the gut microbiome on conditions other than
methodsForty-six potential donors (PDs) had their medical histories and physical examinations undertaken by a physician. Blood, stool, and urine were screened for 31 viral, bacterial, fungal, and protozoan agents in addition to biochemical characteristics. The price of advertising, doctor's visits and diagnostic tests were calculated to determine the cost of finding a donor.
resultsOf the PDs screened, 5 of 46 passed the history, examination, blood, stool, and urine tests. The most common reasons for exclusion included a body mass index >25 or the detection of
conclusionsNew potential therapeutic uses for FMT have created a demand for stricter exclusion criteria for donors. This study illustrates that screening many individuals to find a donor and the subsequent associated costs may make central processing and shipment a more reasonable alternative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.